139 related articles for article (PubMed ID: 23718846)
21. Bortezomib in combination with dexamethasone for a young multiple myeloma with t(8; 14).
Li JY; Wang LX; Shen WY; Lu SF; Chen LJ; Lu H
Leuk Res; 2009 Apr; 33(4):584-6. PubMed ID: 18829108
[No Abstract] [Full Text] [Related]
22. Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient.
Yuan J; Shah R; Kulharya A; Ustun C
Leuk Res; 2010 Jul; 34(7):954-7. PubMed ID: 20138360
[TBL] [Abstract][Full Text] [Related]
23. Mantle cell lymphoma arising in a multiple myeloma patient responding to lenalidomide.
Dasanu CA; Reale MA; Bauer F
Leuk Res; 2010 Jul; 34(7):e178-80. PubMed ID: 20079532
[No Abstract] [Full Text] [Related]
24. Clonal evolution at leukemic relapse of multiple myeloma (secondary plasma cell leukemia) responding to re-treatment with bortezomib-based therapy. A case record.
Bernardeschi P; Pirrotta MT; Montenora I; Giustarini G; Ferreri MI; Simi P; Fiorentini G
Leuk Res; 2010 Apr; 34(4):e104-5. PubMed ID: 19889456
[No Abstract] [Full Text] [Related]
25. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
Palumbo A; Attal M; Roussel M
Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of bortezomib, melphalan and low doses dexamethasone (VM-dex) in newly diagnosed patients with multiple myeloma.
Gozzetti A; Defina M; Bocchia M; Fabbri A; Marchini E; Chitarrelli I; Lauria F
Leuk Res; 2010 Nov; 34(11):e288-9. PubMed ID: 20557933
[No Abstract] [Full Text] [Related]
27. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
[TBL] [Abstract][Full Text] [Related]
28. [Complications and managements in treatment of melphalan, prednisone and new agents].
Ishida T
Nihon Rinsho; 2015 Feb; 73 Suppl 2():649-52. PubMed ID: 25831841
[No Abstract] [Full Text] [Related]
29. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy.
Drach J; Ackermann J; Fritz E; Krömer E; Schuster R; Gisslinger H; DeSantis M; Zojer N; Fiegl M; Roka S; Schuster J; Heinz R; Ludwig H; Huber H
Blood; 1998 Aug; 92(3):802-9. PubMed ID: 9680348
[TBL] [Abstract][Full Text] [Related]
30. Bortezomib in multiple myeloma: treatment and retreatment. A single center experience.
Warzocha K; Kraj M; Pogłód R; Kwaśniak B
Acta Pol Pharm; 2008; 65(6):753-6. PubMed ID: 19172860
[No Abstract] [Full Text] [Related]
31. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Schots R; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Cakana A; van de Velde H; Richardson PG;
N Engl J Med; 2008 Aug; 359(9):906-17. PubMed ID: 18753647
[TBL] [Abstract][Full Text] [Related]
32. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
Palumbo A; Gay F; Falco P; Crippa C; Montefusco V; Patriarca F; Rossini F; Caltagirone S; Benevolo G; Pescosta N; Guglielmelli T; Bringhen S; Offidani M; Giuliani N; Petrucci MT; Musto P; Liberati AM; Rossi G; Corradini P; Boccadoro M
J Clin Oncol; 2010 Feb; 28(5):800-7. PubMed ID: 20048187
[TBL] [Abstract][Full Text] [Related]
33. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
Dimopoulos MA; Roussou M; Gkotzamanidou M; Nikitas N; Psimenou E; Mparmparoussi D; Matsouka C; Spyropoulou-Vlachou M; Terpos E; Kastritis E
Leukemia; 2013 Feb; 27(2):423-9. PubMed ID: 22763386
[TBL] [Abstract][Full Text] [Related]
34. [Hematopoietic stem cell transplantation for multiple myeloma].
Kanda Y
Rinsho Ketsueki; 2009 Oct; 50(10):1420-6. PubMed ID: 19915350
[No Abstract] [Full Text] [Related]
35. DKK1 correlates with response and predicts rapid relapse after autologous stem cell transplantation in multiple myeloma.
Lemaire O; Attal M; Bourin P; Laroche M
Eur J Haematol; 2010 Mar; 84(3):276-7. PubMed ID: 19891699
[No Abstract] [Full Text] [Related]
36. Bortezomib plus melphalan and prednisone for multiple myeloma.
Tsubokura M; Kami M; Komatsu T
N Engl J Med; 2008 Dec; 359(24):2613; author reply 2613-4. PubMed ID: 19090031
[No Abstract] [Full Text] [Related]
37. Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia.
Cheng J; Talamo G; Malysz J; Ochmann M; Lamy T; Loughran TP
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):e169-72. PubMed ID: 25037886
[No Abstract] [Full Text] [Related]
38. Treatment of multiple myeloma in the targeted therapy era.
Saad AA; Sharma M; Higa GM
Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
[TBL] [Abstract][Full Text] [Related]
39. [Multiple myeloma].
Iida S
Rinsho Ketsueki; 2012 Feb; 53(2):155-63. PubMed ID: 22450574
[No Abstract] [Full Text] [Related]
40. [Chemotherapy for multiple myeloma].
Ishida T
Nihon Rinsho; 2007 Dec; 65(12):2280-4. PubMed ID: 18069273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
